CancerNCT00303407
Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care
An observational study of Cancer and Venous Thromboembolism, run by University Hospital, Geneva at 1 site in Switzerland.
Trial summary
To determine the efficacy and to measure the complications of prophylactic anticoagulation using low-molecular weight heparin in adult cancer patients under palliative care Read more about this study
- Who is it for?
- Ages 0 years and older
- Conditions the study is for
- Cancer, Venous Thromboembolism
- What is being tested?
- nadroparin
- How many people
- Not given
- Where
- 1 siteSwitzerland
- Study dates
- Jan 2001to Jul 2002
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 years and older
- All sexes
- Child, Adult, Older adult
Who may be able to join
- Cancer patients in palliative care
- Patients fully informed about their condition
- Signed informed consent
- No exclusion criteria
Who cannot join
- Absence of advanced cancer
- Cancer previously cured
- Venous thromboembolism diagnosed within 6 months prior to inclusion
- Absence of discerning capacity
- Active anti-thrombotic treatment with heparins or coumarines
- Thrombocytopenia <50G/l
Show all 11Show fewer
- PTT >45sec
- TP<35%
- Active bleeding
- Renal failure <20ml/min
- Past history of heparin-induced thrombocytopenia
Trial locations and contacts
1 site in 1 country.
Switzerland1 site
Center of Continuous Care, chemin de la Savonnière
Collonge-Bellerive (Geneva), Canton of Geneva, 1245
About this study
To determine the efficacy and to measure the complications of prophylactic anticoagulation using low-molecular weight heparin in adult cancer patients under palliative care
- Conditions
- Cancer, Venous Thromboembolism
- Being tested
- nadroparin
- Medical subject headings
- Neoplasms, Venous Thromboembolism
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
nadroparinDrug
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Mar 2006 (estimated)
- Study startJan 2001
- Study completionJul 2002
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by University Hospital, GenevaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Defined population
- Time perspective
- Prospective
Sponsor and investigators
- Lead sponsor
- University Hospital, Geneva
- Sponsor type
- University, hospital or other
- Investigators
- Catherine Weber, MD, Principal investigator, Center of Continuous Care, chemin de la Savonnière 11, CH-1245 Collonge-Bellerive
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00303407
- Sponsor's protocol ID
- SPOT 99/54
- Status last verified
- Dec 2005
- First submitted
- 15 Mar 2006
- Last updated
- 16 Mar 2006
- Results posted
- No
Publications
Prandoni P. Antithrombotic strategies in patients with cancer. Thromb Haemost. 1997 Jul;78(1):141-4.
PubMed 9198144
Study at a glance
From the registry record, last updated by the sponsor on 16 Mar 2006. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care
- ClinicalTrials.gov ID
- NCT00303407
- Acronym / sponsor ID
- SPOT 99/54
- Conditions
- Cancer, Venous Thromboembolism
- Study type
- Observational
- Recruitment status
- Terminated
- Lead sponsor
- University Hospital, GenevaUniversity, hospital or other
- Study start
- Jan 2001
- Study completion
- Jul 2002
- First posted
- 16 Mar 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To determine the efficacy and to measure the complications of prophylactic anticoagulation using low-molecular weight heparin in adult cancer patients under palliative care
Study design
- Observational model
- Defined population
- Time perspective
- Prospective
Who may qualify
- Ages
- 0 years and older
- Sex
- All
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- Cancer patients in palliative care
- Patients fully informed about their condition
- Signed informed consent
- No exclusion criteria
Key exclusion criteria (11 listed)
- Absence of advanced cancer
- Cancer previously cured
- Venous thromboembolism diagnosed within 6 months prior to inclusion
- Absence of discerning capacity
- Active anti-thrombotic treatment with heparins or coumarines
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| nadroparin | Drug | – |
Primary outcome
Not reported in the source record.
Results and safety
The study was stopped early. Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Mar 2006.
- Background: PubMed 9198144Prandoni P. Antithrombotic strategies in patients with cancer. Thromb Haemost. 1997 Jul;78(1):141-4.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Catherine Weber, MD principal investigator
Center of Continuous Care, chemin de la Savonnière 11, CH-1245 Collonge-Bellerive
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer and Venous Thromboembolism, run by University Hospital, Geneva at 1 site in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 16 Mar 2006. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early. Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00303407, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2006.